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Abstract 
Aims: The current risk model for percutaneous coronary intervention (PCI) in the UK is 
based on outcomes of patients who were treated in a different era of interventional 
cardiology. This study aimed to create a new model, based on a contemporary cohort of PCI 
treated patients, which would: predict 30 day mortality; provide good discrimination; and 
be well calibrated across a broad risk-spectrum. 
Methods and Results: The model was derived from a training dataset of 336,433 PCI cases 
carried out between 2007 and 2011 in England and Wales, with 30 day mortality provided 
by record linkage. Candidate variables were selected on the basis of clinical consensus and 
data quality. Procedures in 2012 were used to perform temporal validation of the model. 
The strongest predictors of 30-day mortality were: cardiogenic shock; dialysis; and the 
indication for PCI and the degree of urgency with which it was performed. The model had an 
area under the receiver operator characteristic curve of 0.85 on the training data and 0.86 
on validation. Calibration plots indicated a good model fit on development which was 
maintained on validation. 
Conclusion: We have created a contemporary model for PCI that encompasses a range of 
clinical risk, from stable elective PCI to emergency primary PCI and cardiogenic shock. The 
model is easy to apply and based on data reported in national registries. It has a high degree 
of discrimination and is well calibrated across the risk spectrum. The examination of key 
outcomes in PCI audit can be improved with this risk-adjusted model. 
 
Keywords: angioplasty, catheterization, coronary disease, prognosis, risk factors.  
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Introduction 
In the UK National Health Service (NHS), efforts to improve the outcomes of coronary 
revascularisation have received coordinated attention since March 2000 (1). More recently, 
the outcomes for units, and now clinicians, have been published – starting with ten surgical 
domains as part of the “candour” agenda of opening up NHS performance data to public 
scrutiny (2). 
The British Cardiovascular Intervention Society (BCIS, www.bcis.org.uk) is the 
professional body representing all those involved in the field of interventional cardiology. 
Since 2005, BCIS has incorporated patient-level data in its long running annual audit of all 
percutaneous coronary intervention (PCI) procedures performed in the UK. This audit is 
used for benchmarking performance to help improve services and underpin clinical 
governance (3). Due to wide variations in case mix between both operators and PCI centres, 
crude mortality metrics cannot be used to compare clinical and procedural outcomes. Using 
index cases to compare outcomes for patients with more homogenous clinical features has 
several limitations. The preferred approach is to use risk-adjustment techniques that take 
into account the variability of expected outcomes for patients who present with different 
combinations of risk factors (4). 
The North West Quality improvement Program (NWQIP) model has been used for 
risk-adjusted outcomes surveillance since 2006 (5). This model was developed from data on 
patients treated in North West of England between 2001 and 2003. Since then there have 
been major changes in PCI techniques, adjunctive therapies, and in clinical indications for 
PCI. In 2003 the mainstay of treatment for patients with ST elevation myocardial infarction 
(MI) was thrombolysis, but by 2012, over 93% of patients were treated with primary PCI (6). 
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The NWQIP model has been used over this time to adjust for case-mix when auditing the 
outcomes of PCI. Since the NWQIP model was developed, more than a decade ago, there 
have been changes in case-mix and clinical practice, most significantly the systematic uptake 
of primary PCI. Evaluation in a contemporary cohort from the BCIS dataset suggests that 
while the model retains reasonable overall discrimination for major adverse cerebrovascular 
or cardiovascular events (MACCE) it has been subject to significant calibration drift with 
consistent over-prediction of risk (See Supplementary Material). This inaccuracy demands a 
new model based on contemporary data. For UK national audit purposes both the data and 
models need quality assurance. The quality of current adverse event reporting depends on 
local practices at PCI centres. In this regard, in spite of a series of internal validation checks 
on data consistency, there are substantial variations in the quality of the audit data returned 
by different centres (7). 
The aim of this study was to produce an updated robust risk adjustment model with 
good discrimination and correct calibration for contemporary PCI practice in the UK. A 
similar updating exercise has recently been undertaken in the National Cardiovascular Data 
Registry in the US (8). We chose to assess 30 day mortality rather than in-hospital major 
adverse cerebrovascular or cardiovascular event because the former can be derived from 
linkage with Office for National Statistics records (a consistent end point that is not 
influenced by local variation in data completeness). We excluded patients suffering a cardiac 
arrest and being treated outside of hospital prior to PCI because this group contains a 
heterogeneous combination of patients with different risk profiles, and also because of 
concerns that including such patients might lead to inappropriately risk-averse clinical 
behaviour (9). 
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Methods 
Definition of dataset and pre-processing 
The BCIS database comprises 113 variables describing baseline demographics, clinical 
presentation, procedural details and outcomes to hospital discharge. Data for all procedures 
performed in the UK are collected at each PCI centre, encrypted and then uploaded to 
servers now hosted by the National Institute for Clinical Outcomes Research (NICOR) based 
at University College London (3). The Office for National Statistics provides reliable 
independent tracking of mortality (for patients living in England and Wales only), using 
linkage by each patient’s unique identifier. Cases in Scotland and Northern Ireland were 
therefore excluded from the model development. Linkage was carried out by the Medical 
Research Information Service on behalf of NICOR. Analysis was conducted at the University 
of Manchester with Local Research Ethics Committee approval (reference no.11/NW/0694). 
The data were cleaned and analysed using Stata® MP v11.2 (StataCorp LP) 
Although there is no independent validation of data entry, a number of range checks 
and assessments of internal validity are applied as data are uploaded to NICOR. We 
performed a sequence of further procedures to clean the dataset. A number of exclusion 
criteria were applied (Figure 1). We limited our analysis to patients aged over 18 and under 
100 at time of procedure. Patients outside of these age limits are small in number, but could 
contribute disproportionately to outcomes. Patients without tracked mortality data were 
also excluded (this excluded group incorporating all patients from Scotland and Northern 
Ireland). Patients who were ventilated before PCI were also excluded, this field being used 
as a proxy indicator for out of hospital cardiac arrest. 
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A total of 1,112 procedures were identified as likely duplicate entries and were also 
excluded. These were identified by comparing records across age, gender, pseudonymised 
hospital identifier, pseudonymised patient identifier, pseudonymised date of operation, 
month of operation, time of operation, urgency, clinical indication for procedure and status 
at discharge. 
 
Variable selection and definition 
Of the available fields in the BCIS dataset, a shortlist of 10 candidate risk factors was 
identified by the authors on the basis of clinical consensus and data quality. As the model 
was intended to be used to predict outcome before the start of a procedure, variables 
relating to decisions or events occurring during or after the procedure were excluded. 
Age at procedure was given in years and months. For modelling, age was mean-
centred within the development cohort (mean=64.8 years); a quadratic age term was also 
explored. Diabetes was defined as present whether patients were diet controlled, or treated 
with medication including insulin. Serum creatinine levels were only recently added to the 
dataset and were therefore missing in earlier years of the development cohort. However, a 
binary variable indicating whether creatinine measures were greater than 200μmol/l was 
available throughout the time period, so this was used as the measure of renal function. Use 
of dialysis for acute or chronic renal failure was also recorded, and if both this and a 
creatinine measure of >200μmol/l were present, the patient was assigned to the ‘dialysis’ 
group. Patients with functioning transplants were grouped with those who had no renal 
impairment, unless on dialysis or with a creatinine >200µmol/l. 
Definitions of the fields are available online 
(www.ucl.ac.uk/nicor/audits/adultpercutaneous/datasets). Clinical indication for PCI 
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procedure is recorded as one of 12 possible options in the database. For the purposes of 
this model we derived a simpler five-group classification to combine the clinical indication 
and the urgency of the procedure, to avoid the problem of collinearity between these two 
variables. These groups are described in Table 1. 
 
There were insufficient data available on ethnicity of patients to consider this as a variable 
in the model. We did not include a measure of left ventricular ejection fraction as data on 
this characteristic were missing in 50.7% of all patients, and in 67.4% of emergency or 
salvage patients. Furthermore, not only is LV function rarely known at the time of 
emergency PCI for STEMI, but also can be labile following intervention. Sensitivity analysis 
was conducted to evaluate alternative modelling strategies which would enable the 
inclusion of this risk factor; firstly in a model trained only on cases where data on this risk 
factor were available, and secondly on a fully multiply-imputed training dataset. 
 
Missing data handling 
The percentage of data missing in the shortlisted variables is shown in Table 2. Before 
excluding patients aged over 100, in cases where age at procedure was recorded as greater 
than 120 years this was assumed to be erroneous and re-coded as missing. Missing age 
values in the development cohort were replaced with the median by gender within that 
cohort (males 63.6 years, females, 69.6 years). The same values were used to replace 
missing age values in the training cohort, as it was assumed that during model use the 
median population ages might not be available. For categorical variables, missing values 
were assigned to the baseline category i.e. it was assumed that if a risk factor was not 
recorded then it was absent. This represents a plausible missing not at random mechanism 
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that is likely to operate in this case (multiple imputation assumes data are missing at 
random), and incentivises improved data collection practice. It is in line with the approach 
taken by the Society for Cardiothoracic Surgery (11). A sensitivity analysis to assess the 
suitability and potential benefit of using multiple imputation was also conducted. 
 
Model development and validation 
An iterative clinical and stepwise logistic regression modelling approach was used. The 
statistically automated selection of independent variables was based on backward-
elimination via the Akaike information criterion, aiming to optimise model fit. Clinical 
opinion was sought and further refinement of the candidate variable list was made, and 
further modelling was carried out, until we developed a model which was both clinically and 
statistically robust. 
We examined the goodness of fit (calibration) and the ability of the model to 
correctly separate those who went on to have the outcome from those who did not 
(discrimination). We used visual inspection of calibration plots derived from calculating the 
Hosmer-Lemeshow statistic, as opposed to relying on P values for this statistic, which are 
often unreliable with large datasets (12). For assessing discrimination we used the c-statistic, 
which corresponds to the area under the receiver operating characteristic curve (AUC). The 
higher the value of the AUC, the better the model discriminates between true positive 
predictions and true negative predictions. An AUC of 0.5 would indicate a model which is no 
better at predicting the outcome than a random coin toss. In the cardiovascular disease and 
outcome risk prediction literature, reported AUCs are typically in the range of 0.7 to 0.95. 
To improve the calibration of the model, we also explored interaction terms. A 
selection of clinically plausible interactions were tested by introducing them individually into 
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the model. Those which gave a statistically significant contribution to the model were then 
introduced in a forwards stepwise manner with manual selection on the basis of Akaike 
information criterion. In the interests of maintaining parsimony, we restricted the number 
of interaction terms to three. 
The selected model was then validated on data from 2012 (n=76,804) and calibration 
and discrimination tests were performed as above. 
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Results 
Model development 
Of the 336,443 procedures included in the model development dataset from 2007 to 2011, 
a total of 5,722 patients died within 30 days of their procedure (1.7%). Table 3 displays the 
percentage of patients with each risk factor who were either alive or dead within 30 days; 
all risk factors except previous myocardial infarction were found to be statistically 
significantly associated with the outcome using a threshold of P<0.05. In particular, the 
crude 30-day mortality in patients who experienced cardiogenic shock was 29.3% compared 
with 1.3% in those who did not; 7.2% of patients with creatinine >200μmol/l and 5.7% of 
patients on dialysis died compared to 1.6% with no renal impairment. Mortality was higher 
in patients whose procedure was classified as emergency (4.8%) or salvage (17.1%) than 
those whose procedure was elective (0.4%) or urgent (1.3%); salvage procedures being 
those undertaken in the context of a patient being resuscitated en route to the catheter 
laboratory. Similarly, mortality was higher in patients with an acute primary PCI (4.9%) or 
acute non-primary PCI indication (1.5%) than a stable clinical indication (0.4%). 
The final model is shown in Table 4. There were nine independent risk factors in the 
model, all with a statistically highly significant (P<0.001) contribution: mean-centred age, 
female gender, diabetes, previous myocardial infarction, renal disease, history of 
cerebrovascular event, clinical indication/urgency, and cardiogenic shock. Cardiogenic shock 
provided the largest categorical variable coefficient in the model of 3.82 (95% CI 3.43 to 
4.21); this means risk of mortality is higher when that risk factor is present. Clinical 
indication/urgency was also weighted heavily in the model with a coefficient of 2.53 (95% CI 
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2.38 to 2.68) for the highest risk category (group 5) as were dialysis (coefficient 1.13, 95% CI 
0.94 to 1.32) and creatinine >200μmol/l (coefficient 1.00, 95% CI 0.87 to 1.13). 
There were three interaction terms introduced to improve the calibration of the 
model: clinical indication and cardiogenic shock, centred age and cardiogenic shock and 
centred age and diabetes. The negative coefficients associated with these interactions 
effectively correct for over estimation of risk in patients who have both risk factors in the 
interaction pair. The quadratic term for age did not improve the model so was not included. 
 
Model validation 
The validation data from 2012 comprised 75,234 procedures with a 30 day mortality of 
2.09% The validation cohort was similar to the development cohort in terms of patient 
characteristics though patients in the validation cohort were on average slightly older (mean 
age alive=64.9, mean age dead= 74.3) and a far higher percentage of the patients who died 
within 30 days had been classified as salvage procedures (36.2% compared with 17.1% in 
the development cohort). 
Figure 2 illustrates the calibration and discrimination of the model in both 
development and on validation. In development, the model discrimination was good, 
represented by an AUC of 0.848. On validation the discrimination was maintained at a 
similar level, with an AUC of 0.859. This represents discriminative ability at the upper end of 
the range of models in this clinical domain. 
Calibration plots at a range of quantile thresholds indicated a good model fit with 
the development data. Figure 2(iii) shows the calibration plot for 100 risk strata. With the 
development cohort data the calibration plots were slightly less good, but still acceptable: 
Figure 2(iv). To assess the validity of using a single model in spite of a wide range of 
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predicted risk, we assessed its calibration and goodness of fit in the subset of patients being 
treated for ST elevated myocardial infarction by primary PCI and also on the subset being 
treated for stable angina and non-ST elevated myocardial infarction. In both subsets it 
performed well with AUCs of 0.822 and 0.818 respectively. 
 
Sensitivity analysis 
Multiple imputation was conducted as a sensitivity analysis to see if there was any 
additional benefit in using this approach. Overall the model coefficients remained broadly 
consistent under multiple imputation, though the coefficient for cardiogenic shock 
decreased from 3.82 to 3.73 (with a corresponding drop in odds ratio of 45.47 to 41.76). 
There was no difference in the AUC between ‘missing assumed absent’ and multiple 
imputation, as assessed using either the training or validation datasets, nor did calibration 
plots noticeably differ. 
Inclusion of LVEF as a variable in the model under different missing data handling 
frameworks identified that worsening LVEF was associated with a higher odds of 30 day 
mortality. However, the estimated size of the effect was sensitive to the method used. 
When the model was trained only on cases where LVEF data were present, ‘fair’ LVEF (30-
50%) was assigned a coefficient of 0.84 (OR 2.31, 95% CI 2.08-2.56, P<0.001) and ‘poor’ LVEF 
(<30%) had a coefficient of 1.67 (OR 5.31, 95% CI 4.72-5.97, P<0.001). Where multiple 
imputation was used, however, the estimates shrunk: fair LVEF gave 0.28 (OR 1.33, 95% CI 
1.23-1.44, P<0.001) and poor LVEF gave 0.79 (OR 2.19, 95% CI 2.02-2.39, P<0.001). A 
comparison of models where LVEF was or was not included indicated only a small 
incremental improvement in overall model discrimination on its inclusion: in the full training 
set a model without LVEF had an AUC of 0.848 while a model with LVEF had an AUC of 0.852. 
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We decided not to include LV function in our model for a number of reasons. We wanted 
the model to be as parsimonious as possible. The analysis above has shown only a small 
improvement in AUC. Our model needed to be as robust as possible in the setting of a 
National data collection program, where the majority of PCI is performed in an acute setting, 
the likelihood of a significant improvement in data collection for LV function was low in the 
short term, and the variability of LV function in this setting acknowledged but poorly defined. 
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Discussion 
We have created a contemporary PCI mortality model that encompasses a wide range of 
clinical risk, from stable elective PCI to emergency primary PCI and cardiogenic shock. It has 
a high degree of discrimination and is well calibrated across the risk spectrum. 
The overriding aim of clinical audit is to drive up standards of care. This requires that 
important aspects of care are measured so they can be assessed. Robust risk adjustment 
underpins any clinical audit that is used to assess institutional or individual operator 
performance. 
There are several outcomes by which the quality of PCI might be measured. While 
symptom relief is undoubtedly important in patients with stable angina, over 70% of 
patients in the UK are treated in the context of an acute coronary syndrome (7), for which 
mortality is the least biased and arguably most important outcome measure. In addition, 
any national audit is limited by logistic and funding issues. Our experience is that the 
completeness and accuracy of self-reported outcomes varies considerably. Our pragmatic 
solution was to use Office for National Statistics tracked mortality as an outcome because it 
is independent of local data collection heterogeneity. 
The model presented here represents a tool which better reflects contemporary UK 
clinical practice than existing published models. The previous UK NWQIP model (5) reflected 
practice before the era of widespread uptake of primary PCI, was found to be poorly 
calibrated in the assessment of contemporary procedures and therefore a new model was 
required. The new BCIS model does demonstrate some consistency with the previous model, 
despite the differences in outcome and patient population: in both models cardiogenic 
shock and degree of urgency of the procedure are heavily weighted. There are, however, 
several differences. We have opted to consider age as a continuous variable so as to 
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introduce finer granularity of risk assessment in this variable. The BCIS model now includes a 
measure of renal function, while omitting variables relating to the lesions treated. In the 
latter case this was due to an a priori decision to exclude variables relating to the peri-
procedural period; this is pertinent to the model’s intended use for appraisal of operator 
performance, as such variables may be influenced by operator decisions. In keeping with the 
NWQIP model, we have opted to retain the regression model weights rather than derive an 
integer-based score, as the latter is an anachronism of pre-computer clinical prediction. We 
include a measure of renal function, even though this may not be known at the time of 
emergency procedures as we wanted to restrict the model to risk factors present prior to 
procedure, whether known or not at the time of treatment. This is appropriate, given that 
the primary intended purpose of the model is service audit, rather than aiding pre-
procedural clinical decisions. Clinical performance measurement is moving into an era of 
greater openness, transparency and candour. It is no longer acceptable for measures of 
outcome to be used only within professional bodies. Public reporting of outcomes of 
individual operators is intended to drive up standards, and uncloak what has been perceived 
as professional secrecy. In providing patients with much more information, it aims to help a 
rational selection of treatment choices, and to promote a better understanding of expected 
outcomes. It demonstrates to the public that quality of care is being actively monitored and 
improved where necessary. Public reporting also encourages healthcare organisations to 
focus on recording and providing more complete and accurate information. 
An important problem with public reporting is that it can precipitate risk-averse 
clinical decisions, disadvantaging the sickest patients who have the most to benefit from 
interventions (13–16). If a model under-predicts risk in high risk cases, then a cardiologist 
taking on these cases may be incorrectly assessed to be underperforming, and recognising 
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this will be anxious to avoid treating such patients. In the UK, cardiothoracic surgeons have 
been reporting outcome data for some years (17). In a recent analysis of the performance of 
EuroSCORE II they demonstrated that it was poorly calibrated and had weak discrimination 
for emergency cardiac surgery (18). As a result such cases are currently excluded from 
reports. It is therefore critically important that the model we have created performs well at 
extremes of risk. However, in the setting of out of hospital cardiac arrest no satisfactory risk 
model currently exists, and to reduce the potential harm from risk-averse clinical behaviour  
over patients presenting in this way, we decided to excluded them both from this model, 
and from public reporting of PCI outcomes in the UK for the time being (9). 
 
Limitations 
Although the BCIS audit programme applies to all UK procedures, the model was fit using 
only data from England and Wales, since record linkage via Office for National Statistics is 
available only for these patients. This does, however, present opportunity for validation 
studies in Scotland and Northern Ireland; these regions may have different patterns of risk 
factors and mortality, adding useful heterogeneity to the extended validation of this model. 
Further temporal validation should be conducted in future years to ensure the performance 
of the model remains acceptable, with recalibration performed as necessary (19,20). 
It is possible that the discrimination of this model would improve with the addition 
of further risk factors. Lack of sufficient data on left ventricular ejection fraction (LVEF) was 
a notable limitation of our data resource. The Toronto PCI in-hospital mortality score, which 
has an AUC of 0.96, incorporates a binary measure of LVEF, assigning an odds ratio of 1.40 
to patients with LVEF of <20%. Both this model and the US National Cardiovascular Disease 
registry in-hospital mortality model (AUC of 0.93) (8) incorporated measures of estimated 
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glomerular filtration rate into models, rather than using a binary creatinine threshold as we 
have done here. It is intended that in future updates to the BCIS model, we will consider 
estimated glomerular filtration rate for incorporation, as improved collection of data on 
these risk factors is mandated in future data collection. Left ventricular function was not 
included in the model as this was missing in 50.7% of cases. Additional reasons have been 
discussed above but inclusion did not add usefully to AUC. 
Our practice of replacing missing categorical values with null values may lead to biased 
estimates of individual patient risk. This will cause bias if some centres or operators are 
systematically under-reporting the presence of risk factors. However, we found no benefit 
to be had from conducting multiple imputation, and it may be more productive to focus 
efforts on reducing missing data at source in future years of the audit. Given the additional 
complexity of applying the model in a multiple imputation framework, and the fact that data 
may be missing in patterns other than random, our approach is appropriate at this time. 
 
Due to limitations imposed by the data sharing framework, we did not have access 
to un-pseudonymised procedure date. It was therefore not possible to identify redo 
procedures (i.e. those which were a second attempt), which may have led to some double 
counting of procedures or potential underestimation of the mortality burden of the index 
procedure in cases where a patient died following a redo procedure. We hope the 
establishment of “safe havens” for analysis by national organisations such as the Farr 
Institute will enable such analyses in the future, better serving patients with proportionate 
governance of their information (21). 
 
Future research 
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We intend to validate the model further, and monitor the calibration and discrimination 
performance over time, updating as necessary. Future updates of the model will likely 
incorporate established or emerging risk factors that we were not able to include in this 
version. 
In addition, we are investigating dynamic modelling approaches that will run 
continuous statistical surveillance of model performance and prompt the clinical audit team 
over possible calibration drift and potential structural deterioration of the model. Where 
factors such as renal function are under-represented due to data quality they can be kept on 
watch for fuller inclusion as the data are better collected. In addition, there is a need to 
study the effects of different forms of audit feedback on data collection and quality. 
Conclusions 
We have generated a new parsimonious and contemporary model for predicting risk of 30-
day mortality in patients undergoing PCI in the UK. It shows good discrimination and 
calibration across a wide spectrum of risk. It takes into account the marked changes to the 
performance of PCI in recent years and is independent of variations in completeness of 
adverse event reporting and therefore is a more appropriate choice of model for the BCIS 
national audit programme. 
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Figure Legends 
 
Figure 1: Flow chart illustrating creation of analysis and validation dataset from the available 
records in the BCIS database. 
 
Figure 2: Illustrations of model discrimination and calibration. (i) receiver operating 
characteristic curve of model on development data (2007-2011) (ii) receiver operating 
characteristic curve of model when applied to validation data (2012) (iii) calibration plot 100 
quantiles) for model in development (iv) calibration plot (100 quantiles) for model on 
validation 
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Tables 
Table 1. Groupings of BCIS field entries for clinical indication for procedure, to give a five-group 
classification of procedural type and urgency. 
Group Indication/urgency 
1 “stable – angina” OR 
“stable – coronary/LV anatomy” OR 
“staged procedure” OR 
“hybrid procedure”  
 
2 “ACS - UA, NSTEMI or convalescent STEMI” AND “urgent” 
 
3 “ACS - UA, NSTEMI or convalescent STEMI” AND “emergency” OR 
“ACS - UA, NSTEMI or convalescent STEMI” AND “salvage” 
 
4 “ACS - Primary PCI for STEMI (no lysis)” OR 
“ACS - Facilitated PCI for STEMI (lysis + PCI)” OR 
“Acute or sub-acute PCI thrombosis” OR 
“Bail out following acute complication of diagnostic cardiac catheterisation”  
 
5 “ACS - Rescue PCI for STEMI (failed lysis)” OR 
“ACS - PCI for re-infarction (no lysis)” OR 
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“ACS - Rescue PCI for re-infarction (failed lysis)” 
ACS=acute coronary syndrome; LV= Left ventricular; UA= unstable angina; NSTEMI= non ST 
elevated myocardial infarction; STEMI=ST elevated myocardial infarction 
 
Table 2. Frequency and % of missing data for each variable included in the model 
  
Training data (2007-
2011); n= 336,433 
Validation data (2012); 
n = 76,804 
Variable 
n 
missing 
% missing 
n 
missing 
% missing 
age at procedure 166 0.05 9 0.01 
gender 754 0.22 90 0.12 
diabetes 13998 4.16 4144 5.40 
urgency of procedure 361 0.11 105 0.14 
previous CABG 16716 4.97 1763 2.30 
previous MI 38956 11.58 5702 7.42 
renal disease 18608 5.53 3349 4.36 
indication for intervention 5831 1.73 233 0.30 
history of cerebrovascular event 146 0.04 42 0.05 
cardiogenic shock 24269 7.21 3593 4.68 
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Table 3. Patient characteristics and crude mortality rates (%) for each variable in the training and validation datasets. 
   Training dataset (2007-2011) Validation dataset (2012) 
   alive (n=330,711) dead (n=5,722)   alive (n=75,234) dead (n=1,570)   
    n % n %  P n % n % P 
gender Male 245,884 98.52 3,701 1.48 <0.001 55,945 98.33 952 1.67 <0.001 
  Female 84,827 97.67 2,021 2.33   19,289 96.90 618 3.10   
diabetic No 272,427 98.43 4,354 1.57 <0.001 60,847 98.13 1,161 1.87 <0.001 
  
Yes (diet 
controlled, oral 
Rx, insulin) 58,284 97.71 1,368 2.29 
  
14,387 97.24 409 2.76 
  
urgency Elective 139,894 99.64 501 0.36 <0.001 27,220 99.68 88 0.32 <0.001 
 Urgent 118,416 98.75 1,499 1.25   26,196 98.71 342 1.29  
 Emergency 71,834 95.22 3,605 4.78   21,774 95.13 1,115 4.87  
  Salvage 567 82.89 117 17.11   44 63.77 25 36.23   
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previous CABG No 303,359 98.27 5,335 1.73 <0.001 69,169 97.91 1,476 2.09 0.003 
  Yes 27,352 98.60 387 1.40   6,065 98.47 94 1.53   
previous MI No 247,273 98.32 4,222 1.68 0.089 57,124 97.98 1,179 2.02 <0.001 
  Yes 83,438 98.23 1,500 1.77   18,110 97.89 391 2.11   
previous PCI No 247,462 98.19 4,568 1.81 <0.001 56,075 97.79 1,270 2.21 <0.001 
  Yes 68,611 98.82 821 1.18   17,202 98.69 228 1.31   
renal 
disease/dysfunction 
None 323,822 98.41 5,231 1.59 <0.001 73,475 98.08 1,439 1.92 <0.001 
Creatinine >200 
μmol/l 4,481 92.85 345 7.15 
  
1,177 93.12 87 6.88 
 
Dialysis 2,408 94.28 146 5.72   582 92.97 44 7.03   
indication Stable 142,330 99.59 587 0.41 <0.001 27,383 99.67 90 0.33 <0.001 
 
Acute, not 
primary 124,665 98.53 1,861 1.47 
  
27,727 98.39 453 1.61 
 
 Acute, primary 62,870 95.15 3,208 4.85   19,929 95.17 1,011 4.83  
  Other 846 92.76 66 7.24   195 92.42 16 7.58   
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History of 
cerebrovascular 
event 
No 
318,867 98.39 5,234 1.61 
<0.001 
72,326 98.07 1,423 1.93 
<0.001 
  Yes 11,844 96.04 488 3.96   2,908 95.19 147 4.81   
cardiogenic shock No 327,392 98.69 4,345 1.31 <0.001 74,372 98.45 1,171 1.55 <0.001 
  Yes 3,319 70.68 1,377 29.32   862 68.36 399 31.64   
age Mean age at 
procedure 
64.6 (95% CI 64.6 
to 64.7)  
73.3 (95% CI 73.0 
to 73.6) 
<0.001 
64.9 (95% CI 64.8 
to 64.9) 
74.3 (95% CI 73.7 
to 74.8) 
<0.001 
Median age at 
procedure 64.9 (IQR 17) 75 (IQR 16) 
  
65 (IQR 18) 76 (IQR 16) 
 
P values indicate results of statistical comparisons within datasets of patients recorded alive vs dead at 30 days (Chi squared test for 
categorical variables, t test for age). 
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Table 4. The final logistic regression model.  
Risk prediction is then carried out by summing constant and all coefficients where a risk 
factor is present to derive the log odds. 64.8 is subtracted from age before multiplying by 
coefficient. Interaction coefficients are used when both interacting features are present. 
For example, a 75-year old male with diabetes, in urgency group 2 would have  
log-odds = -6.089 + 0.071*(75-64.8) + 0.524 + 1.004 + (-0.016) x (75-64.8) = -4.000. 
This can be converted to a probability: p = 100/(1+exp(-(-4.000))) = 1.80%. 
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 Coefficient 
- log odds 
Odds 
ratio 
Odds 
ratio 
Lower CI 
bound 
Odds 
ratio 
Upper CI 
bound p 
centred age  0.071 1.073 1.069 1.077 <0.001 
female sex  0.114 1.121 1.056 1.190 <0.001 
diabetes      0.524 1.689 1.557 1.831 <0.001 
previous MI  0.158 1.171 1.097 1.251 <0.001 
renal disease       
 creatinine 0.997 2.708 2.378 3.087 <0.001 
 dialysis 1.128 3.090 2.557 3.735 <0.001 
                    
cerebrovascular event  0.430 1.537 1.385 1.706 <0.001 
indication-urgency       
 group 2 1.004 2.729 2.470 3.014 <0.001 
 group 3 2.114 8.283 7.126 9.629 <0.001 
 group 4 2.295 9.921 9.013 10.921 <0.001 
 group 5 2.531 12.561 10.788 14.656 <0.001 
                    
cardiogenic shock  3.817 45.473 30.721 67.309 <0.001 
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age-shock interaction  -0.026 0.975 0.968 0.982 <0.001 
indication-shock 
interaction 
      
 group 2 -0.951 0.386 0.246 0.605 <0.001 
 group 3 -1.226 0.294 0.185 0.465 <0.001 
 group 4 -1.203 0.300 0.201 0.449 <0.001 
 group 5 -1.438 0.237 0.149 0.377 <0.001 
                    
age-diabetes interaction  -0.016 0.984 0.977 0.990 <0.001 
Constant/intercept  -6.089 0.002 0.002 0.003 <0.001 
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